| 英文名称 | Palazestrant (Synonyms: OP-1250) |
|---|---|
| 中文名称 | (1R,3R)-2-(2-氟-2-甲基丙基)-3-甲基-1-(4-((1-丙基氮杂环丁烷-3-基)氧基)苯基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚;帕拉司群 |
| CAS号 | 2092925-89-6 |
| 分子式 | C28H36FN3O |
| 分子量 | 449.60 |
| 英文名称 | Palazestrant (Synonyms: OP-1250) |
|---|---|
| 中文名称 | (1R,3R)-2-(2-氟-2-甲基丙基)-3-甲基-1-(4-((1-丙基氮杂环丁烷-3-基)氧基)苯基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚;帕拉司群 |
| CAS号 | 2092925-89-6 |
| 分子式 | C28H36FN3O |
| 分子量 | 449.60 |
Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM. Palazestrant can inhibit ER+/HER2+ cancer.